R&D IN BRIEF

 
• By Pharmaceutical Approvals Monthly

QuatRx starts second pivotal trial for its SERM Ophena; Arcalyst significantly reduces gout flares; Novartis dumps antibiotic add-on Aurograb; more R&D, in brief

More from Archive

More from Pink Sheet